Skip to main content
Erschienen in: Pathology & Oncology Research 3/2019

27.11.2018 | Original Article

Patterns of Regression in Breast Cancer after Primary Systemic Treatment

verfasst von: Tamás Zombori, Gábor Cserni

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Despite national guidelines, the evaluation of effects of primary systemic treatment (PST) in breast cancer is a complex challenge. Our aims were to evaluate the response patterns focusing on correlations of radiological and pathological tumor size, regression heterogeneity in different molecular subtypes, cellularity changes and the incidence of enlarged, multinucleated neoplastic cells related to therapy. Slides of pretreatment biopsies and resection specimens of consecutive cases were reevaluated focusing on heterogeneity of regression per whole slide, and 40x or 100x magnification fields. Alteration in cellularity and the presence of multinucleated tumor giant cells were noted. The correlation of pathological and radiological sizes and their alterations were analyzed by Spearman rank correlation. The present study included 106 tumors. A decrease in size (84.9%) and cellularity (76.4%) was noted in all molecular subtypes. Inhomogeneous regression was found in 45.3%, with minor inhomogeneity in the majority. Scatter pattern regression was seen only in 8 cases (7.5%). Significant correlations were found between the pathological and radiological sizes (p = 0.02), and between the alterations of cellularity and pathological and radiological size (p = 0.04; p = 0.03, respectively). Multinucleated tumor giant cells were noted in 17.9% (n = 19), nearly exclusively in cases treated with PST including taxanes. Regression inhomogeneity following PST is present in about half of the cases, and is not related to molecular subtypes. The evaluation of the maximum area of the tumor bed is recommended for the proper evaluation of regression. Multinucleated tumor giant cells are related to PST including taxane derivate, and may cause upgrading.
Literatur
3.
Zurück zum Zitat Lambein K, Van de Vijver K, Faverly D, Colpaert C (2011) Belgian guidelines for laboratory handling and pathology reporting of breast carcinoma after neoadjuvant therapy. Belg J Med Oncol 5:144–153 Lambein K, Van de Vijver K, Faverly D, Colpaert C (2011) Belgian guidelines for laboratory handling and pathology reporting of breast carcinoma after neoadjuvant therapy. Belg J Med Oncol 5:144–153
5.
Zurück zum Zitat NHS Breast Screening Program (2005) Pathology reporting of breast disease: a joint document incorporating the third edition of the NHS breast screening programs guidelines for pathology reporting in breast cancer screening and the second edition of the Royal College of pathologists’ minimum dataset for breast cancer histopathology. NHSBSP publication no 58. NHS Cancer screening programs jointly with the Royal College of pathologists NHS Breast Screening Program (2005) Pathology reporting of breast disease: a joint document incorporating the third edition of the NHS breast screening programs guidelines for pathology reporting in breast cancer screening and the second edition of the Royal College of pathologists’ minimum dataset for breast cancer histopathology. NHSBSP publication no 58. NHS Cancer screening programs jointly with the Royal College of pathologists
8.
Zurück zum Zitat Cserni G, Kulka J, Francz M, Járay B, Kálmán E, Kovács I, Krenács T, Udvarhelyi N, Vass L (2016) Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 3rd Hungarian consensus conference on breast Cancer. Magy Onkol 60:209-28 (Hungarian) Cserni G, Kulka J, Francz M, Járay B, Kálmán E, Kovács I, Krenács T, Udvarhelyi N, Vass L (2016) Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 3rd Hungarian consensus conference on breast Cancer. Magy Onkol 60:209-28 (Hungarian)
10.
Zurück zum Zitat Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF (2015) Residual disease characterization working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 28:1185–1201. https://doi.org/10.1038/modpathol.2015.74 CrossRefPubMed Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF (2015) Residual disease characterization working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 28:1185–1201. https://​doi.​org/​10.​1038/​modpathol.​2015.​74 CrossRefPubMed
13.
Zurück zum Zitat AJCC (2016) Cancer staging manual, 8th edn. Springer, Chicago AJCC (2016) Cancer staging manual, 8th edn. Springer, Chicago
14.
Zurück zum Zitat Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172. https://doi.org/10.1016/S0140-6736(13)62422-8 CrossRefPubMed Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172. https://​doi.​org/​10.​1016/​S0140-6736(13)62422-8 CrossRefPubMed
15.
Zurück zum Zitat von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804. https://doi.org/10.1200/JCO.2011.38.8595 CrossRef von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804. https://​doi.​org/​10.​1200/​JCO.​2011.​38.​8595 CrossRef
18.
Zurück zum Zitat Denkert C, Schickling O, von Minckwitz G (2006) Preoperative chemotherapy in breast cancer and the development of new predictive markers. Verh Dtsch Ges Pathol 114-23(German):90 Denkert C, Schickling O, von Minckwitz G (2006) Preoperative chemotherapy in breast cancer and the development of new predictive markers. Verh Dtsch Ges Pathol 114-23(German):90
19.
Zurück zum Zitat Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180:297–306PubMed Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180:297–306PubMed
20.
Zurück zum Zitat Wells CA, Amendoeira I, Bellocq JP, Bianchi S, Boecker W, Borisch B, Bruun Rasmussen B, Callagy GM, Chmielik E, Cordoba A, Cserni G, Decker T, DeGaetano J, Drijkoningen M, Ellis IO, Faverly DR, Foschini MP, Frković-Grazio S, Grabau D, Heikkilä P, Iacovou E, Jacquemier J, Kaya H, Kulka J, Lacerda M, Liepniece-Karele I, Martinez-Penuela J, Quinn CM, Rank F, Regitnig P, Reiner-Concin A, Sapino A, Tot T, Van Diest PJ, Varga Z, Wesseling J, Zolota V, Zozaya-Alvarez E. (2012) Pathology update. Quality assurance guidelines for pathology. In: European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition, Supplements. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds.). European Commission, Office for Official Publications of the European Union, Luxembourg, pp. 73–120 Wells CA, Amendoeira I, Bellocq JP, Bianchi S, Boecker W, Borisch B, Bruun Rasmussen B, Callagy GM, Chmielik E, Cordoba A, Cserni G, Decker T, DeGaetano J, Drijkoningen M, Ellis IO, Faverly DR, Foschini MP, Frković-Grazio S, Grabau D, Heikkilä P, Iacovou E, Jacquemier J, Kaya H, Kulka J, Lacerda M, Liepniece-Karele I, Martinez-Penuela J, Quinn CM, Rank F, Regitnig P, Reiner-Concin A, Sapino A, Tot T, Van Diest PJ, Varga Z, Wesseling J, Zolota V, Zozaya-Alvarez E. (2012) Pathology update. Quality assurance guidelines for pathology. In: European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition, Supplements. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds.). European Commission, Office for Official Publications of the European Union, Luxembourg, pp. 73–120
22.
Zurück zum Zitat Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, Modi S, Patt DA, Perlmutter J, Ramakrishna N, Winer EP, Davidson NE (2018) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol [Epub ahead of print]. https://doi.org/10.1200/JCO.2018.79.2697 Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, Modi S, Patt DA, Perlmutter J, Ramakrishna N, Winer EP, Davidson NE (2018) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol [Epub ahead of print]. https://​doi.​org/​10.​1200/​JCO.​2018.​79.​2697
23.
Zurück zum Zitat Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600–2608. https://doi.org/10.1200/JCO.2003.01.136 CrossRefPubMed Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600–2608. https://​doi.​org/​10.​1200/​JCO.​2003.​01.​136 CrossRefPubMed
24.
Zurück zum Zitat Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940–1949. https://doi.org/10.1200/JCO.2005.02.6187 CrossRefPubMed Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940–1949. https://​doi.​org/​10.​1200/​JCO.​2005.​02.​6187 CrossRefPubMed
25.
Zurück zum Zitat von Minckwitz G, Blohmer JU, Raab G, Löhr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, Zuna I, Costa SD, German Breast Group (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16:56–63. https://doi.org/10.1093/annonc/mdi001 CrossRef von Minckwitz G, Blohmer JU, Raab G, Löhr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, Zuna I, Costa SD, German Breast Group (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16:56–63. https://​doi.​org/​10.​1093/​annonc/​mdi001 CrossRef
27.
Zurück zum Zitat Marinovich ML, Macaskill P, Irwig L, Sardanelli F, Mamounas E, von Minckwitz G, Guarneri V, Partridge SC, Wright FC, Choi JH, Bhattacharyya M, Martincich L, Yeh E, Londero V, Houssami N (2015) Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer 15:662. https://doi.org/10.1186/s12885-015-1664-4 CrossRefPubMedPubMedCentral Marinovich ML, Macaskill P, Irwig L, Sardanelli F, Mamounas E, von Minckwitz G, Guarneri V, Partridge SC, Wright FC, Choi JH, Bhattacharyya M, Martincich L, Yeh E, Londero V, Houssami N (2015) Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer 15:662. https://​doi.​org/​10.​1186/​s12885-015-1664-4 CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF (2004) Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 100:1365–1373. https://doi.org/10.1002/cncr.20134 CrossRefPubMed Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF (2004) Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 100:1365–1373. https://​doi.​org/​10.​1002/​cncr.​20134 CrossRefPubMed
30.
Zurück zum Zitat Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Curé H, Chollet P (2005) High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94:255–263. https://doi.org/10.1007/s10549-005-9008-8 CrossRefPubMed Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Curé H, Chollet P (2005) High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94:255–263. https://​doi.​org/​10.​1007/​s10549-005-9008-8 CrossRefPubMed
33.
Zurück zum Zitat Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT, Graham ML (2005) American joint committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97:1137–1142. https://doi.org/10.1093/jnci/dji206 CrossRefPubMed Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT, Graham ML (2005) American joint committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97:1137–1142. https://​doi.​org/​10.​1093/​jnci/​dji206 CrossRefPubMed
38.
Zurück zum Zitat Leary A, Evans A, Johnston SR, A'Hern R, Bliss JM, Sahoo R, Detre S, Haynes BP, Hills M, Harper-Wynne C, Bundred N, Coombes G, Smith I, Dowsett M (2015) Antiproliferative effect of Lapatinib in HER2-positive and HER2-negative/HER3-high breast cancer: results of the presurgical randomized MAPLE trial (CRUKE/06/039). Clin Cancer Res 21:2932–2940. https://doi.org/10.1158/1078-0432.CCR-14-1428 CrossRefPubMed Leary A, Evans A, Johnston SR, A'Hern R, Bliss JM, Sahoo R, Detre S, Haynes BP, Hills M, Harper-Wynne C, Bundred N, Coombes G, Smith I, Dowsett M (2015) Antiproliferative effect of Lapatinib in HER2-positive and HER2-negative/HER3-high breast cancer: results of the presurgical randomized MAPLE trial (CRUKE/06/039). Clin Cancer Res 21:2932–2940. https://​doi.​org/​10.​1158/​1078-0432.​CCR-14-1428 CrossRefPubMed
39.
Zurück zum Zitat Honkoop AH, Pinedo HM, De Jong JS, Verheul HM, Linn SC, Hoekman K, Wagstaff J, van Diest PJ (1997) Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 107:211–218CrossRefPubMed Honkoop AH, Pinedo HM, De Jong JS, Verheul HM, Linn SC, Hoekman K, Wagstaff J, van Diest PJ (1997) Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 107:211–218CrossRefPubMed
40.
Zurück zum Zitat Sharkey FE, Addington SL, Fowler LJ, Page CP, Cruz AB (1996) Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol 9:893–900PubMed Sharkey FE, Addington SL, Fowler LJ, Page CP, Cruz AB (1996) Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol 9:893–900PubMed
42.
Zurück zum Zitat Fukada I, Araki K, Kobayashi K, Shibayama T, Takahashi S, Gomi N, Kokubu Y, Oikado K, Horii R, Akiyama F, Iwase T, Ohno S, Hatake K, Sata N, Ito Y (2018) Pattern of tumor shrinkage during neoadjuvant chemotherapy is associated with prognosis in low-grade luminal early breast cancer. Radiology 286:49–57. https://doi.org/10.1148/radiol.2017161548 CrossRefPubMed Fukada I, Araki K, Kobayashi K, Shibayama T, Takahashi S, Gomi N, Kokubu Y, Oikado K, Horii R, Akiyama F, Iwase T, Ohno S, Hatake K, Sata N, Ito Y (2018) Pattern of tumor shrinkage during neoadjuvant chemotherapy is associated with prognosis in low-grade luminal early breast cancer. Radiology 286:49–57. https://​doi.​org/​10.​1148/​radiol.​2017161548 CrossRefPubMed
Metadaten
Titel
Patterns of Regression in Breast Cancer after Primary Systemic Treatment
verfasst von
Tamás Zombori
Gábor Cserni
Publikationsdatum
27.11.2018
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0557-7

Weitere Artikel der Ausgabe 3/2019

Pathology & Oncology Research 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.